Previous Page  13 / 48 Next Page
Information
Show Menu
Previous Page 13 / 48 Next Page
Page Background www.salk.edu

Inside Salk 12 |15

Feature

13

W

HEN BILL BRODY RETIRES AS PRESIDENT OF

the Salk Institute at the end of December 2015,

it will mark the close of a fruitful chapter for the

Institute and the beginning of a new era. An acclaimed physi-

cian-scientist entrepreneur and university leader, Brody joined

Salk in 2009 after serving 12 years as president of Johns

Hopkins University. During Brody’s six years of leadership at

Salk, he navigated the Institute through challenging waters,

weathering a global financial crisis while launching Salk’s first

major fundraising campaign. The Campaign for Salk significantly

boosted the Institute’s outreach efforts to raise its profile and

attract private philanthropic support. This included a number of

new public events, including the Salk Science & Music Series,

Brody’s brainchild and an offshoot of his classical piano training.

As Brody steps down as president this month, the campaign

comes to a close, having exceeded the goal of raising $300

million and more than doubling the Institute’s endowment

from $132 million in 2009 to $356 million in 2015—laying a

financial foundation critical to long-term stability and flexibility.

In addition to shoring up its financial footing, the Institute

has boasted a run of scientific successes during Brody’s tenure,

including recruiting a new cadre of highly sought-after faculty

and expanding its research facilities, outfitting them with the

most cutting-edge scientific technologies. Most important of

all, Salk’s scientists continue to produce a steady stream of

remarkable scientific discoveries that are changing how we

see the world and how we tackle the many challenges facing

humanity, from climate change to Alzheimer’s disease to cancer.

THE FUTURE ALWAYS HOLDS

OPPORTUNITIES AND CHALLENGES.

– BILL BRODY

What do you see as the best opportunities

for the Salk Institute?

We have so many opportunities—too many, really. We’re living in

a renaissance of biomedical science. People say this is the ‘era

of stem cells’ or ‘neuroscience’ or ‘cancer.’ And that’s all true.

One challenge at Salk is all the technologies we have to deal

with. We are the Salk Institute for Biological Studies—not tech-

nological studies—but it’s critically important that we invest in

technology. Technology is really driving the science now. Another

promising trend I’ve seen at Salk is the merging of basic and

translational research. It used to be that someone who discovered

Bill Brody and Irwin Jacobs, chairman of Salk’s Board of Trustees